Using Pharmacogenomics (PGx) Results to Guide Post-operative Nausea and Vomiting (PONV) Treatment Practices: A Pilot Study
Overview
- Phase
- Phase 4
- Intervention
- Granisetron
- Conditions
- Postoperative Nausea
- Sponsor
- Mayo Clinic
- Enrollment
- 92
- Locations
- 1
- Primary Endpoint
- Episodes of Postoperative Vomiting
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic data to guide post-operative nausea and vomiting treatment in the bariatric surgical population. The hypothesis is that using genotypic variation in CYP2D6 to select the appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in the bariatric surgical population.
Investigators
Yvette N. Martin, MD-PhD
Principal Investigator
Mayo Clinic
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
CYP2D6 rapid metabolizer
Participants with CYP2D6 rapid metabolizer status will received granisetron for for post operative nausea and vomiting prophylaxis and treatment
Intervention: Granisetron
CYP2D6 normal metabolizer
Participants with CYP2D6 poor or normal metabolizer status will received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment
Intervention: Ondansetron
Outcomes
Primary Outcomes
Episodes of Postoperative Vomiting
Time Frame: 0-48 hours post bariatric surgery
The total number count of post operative vomiting episodes were determined by nursing documentation or by treatment with rescue antinausea medication.
Episodes of Postoperative Nausea
Time Frame: 0-48 hours post bariatric surgery
The total number count of post operative nausea episodes were determined by nursing documentation or by treatment with rescue antinausea medication.